Key result
Remdesivir is linked to reversible sinus bradycardia and QTc prolongation in severe COVID-19 pneumonia.
Why the study?
Does Remdesivir therapy cause bradycardia in hospitalized patients with severe COVID-19 pneumonia?
Population
Two patients with severe COVID-19 pneumonia and worsening oxygen requirements
Comparison
Remdesivir therapy
Design
Two case reports
Authors
Loading...
May warrant ECG monitoring with remdesivir in severe COVID-19; leaves open causality and incidence.
Case Report (n=2)
Does Remdesivir therapy cause bradycardia in hospitalized patients with severe COVID-19 pneumonia?
Remdesivir therapy in severe COVID-19 patients may be associated with reversible sinus bradycardia and QTc prolongation, highlighting the need for close cardiac monitoring.
Abdelmajid et al. (2021) conducted a case report in Severe COVID-19 pneumonia (n=2). Remdesivir was evaluated on Sinus bradycardia. Remdesivir therapy was associated with the development of reversible sinus bradycardia in two patients with severe COVID-19 pneumonia, with one also developing QTc interval prolongation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: